Severe acute respiratory syndrome-related coronavirus

STERAMIST DEPLOYED TO FIGHT SARS CoV-2 CORONAVIRUS IN THE UNITED STATES

Retrieved on: 
Monday, March 16, 2020
Viruses, Coronaviridae, Zoonoses, Animal virology, Coronavirus, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, CoV, Orthocoronavirinae, SARS coronavirus main proteinase

TOMI Service Network (TSN) and BIT solution sales have rapidly increased across the United States in an effort to combat SARS CoV-2 coronavirus.

Key Points: 
  • TOMI Service Network (TSN) and BIT solution sales have rapidly increased across the United States in an effort to combat SARS CoV-2 coronavirus.
  • The TSN division is a network comprised of independent service professionals across the United States and Canada.
  • As businesses ready themselves with action plans for potential SARS CoV-2 coronavirus exposure, TOMI has seen a steadily increasing stream of SteraMist inquiries.
  • Many established companies are joining the TSN to add SteraMist to their service offerings to assist in combatting the spread of SARS CoV-2 coronavirus.

Twist Announces Availability of Next-Generation Sequencing Target Enrichment Panel for SARS-CoV-2/COVID-19 Research

Retrieved on: 
Monday, March 16, 2020
Biotechnology, Hardware, Health, Data management, Infectious diseases, Technology, Genetics, Clinical trials, Viruses, Nidovirales, Zoonoses, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Animal virology, Coronaviridae, Middle East respiratory syndrome

We encourage the entire research community to come together as a global force to fight this pandemic leveraging our individual strengths for the greater good.

Key Points: 
  • We encourage the entire research community to come together as a global force to fight this pandemic leveraging our individual strengths for the greater good.
  • Using its silicon-based DNA synthesis platform, Twist now offers a suite of research products for the study of SARS-CoV-2 and COVID-19.
  • Twist is offering its newest target enrichment panel in three reaction sizes to facilitate various workflows, with synthetic double-stranded DNA probes covering the entire length of the SARS-CoV-2 virus.
  • The Twist SARS-CoV-2 research panel provides excellent limit of detection in challenging samples due to the advanced probe design and coverage uniformity.

Beyond Air Submits Investigational Device Exemption (IDE) to the United States Food and Drug Administration (FDA) for the Treatment of COVID-19 Patients

Retrieved on: 
Monday, March 16, 2020
Medicine, Viruses, Health, Zoonoses, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Oxygen therapy

The primary endpoint is time to clinical improvement based on key parameters such as fever and oxygen support.

Key Points: 
  • The primary endpoint is time to clinical improvement based on key parameters such as fever and oxygen support.
  • Otherprotocols targeting people exposed to SARS-CoV-2, the virus that causes COVID-19, are being designed to show that treatment with NO may prevent infection.
  • Beyond Air has already generated relevant data in humans, as shown at its Analyst Day held on March 5, 2020 (replay available at www.beyondair.net ).
  • For the first time, Beyond Air intends to offer NO treatment in the home setting with the elimination of cylinders.

Asuragen Develops Armored RNA Quant® SARS-CoV-2 Control

Retrieved on: 
Monday, March 16, 2020
Biotechnology, Technology, FDA, Managed care, Health, Pharmaceutical, Medical devices, Infectious diseases, Software, Hospitals, Genetics, Viruses, Zoonoses, Coronaviridae, Animal virology, Severe acute respiratory syndrome-related coronavirus, Middle East respiratory syndrome-related coronavirus, Coronavirus, Severe acute respiratory syndrome, CoV, RNA

Asuragen, Inc. has developed an Armored RNA Quant SARS-CoV-2 Control for use in developing assays in response to the COVID-19 pandemic.

Key Points: 
  • Asuragen, Inc. has developed an Armored RNA Quant SARS-CoV-2 Control for use in developing assays in response to the COVID-19 pandemic.
  • Asuragens proprietary Armored RNA Quant technology has been included in FDA-approved assays for over 20 years and is the gold standard for reliable, traceable standards for use with molecular assays developed for virus quantitation.
  • The Armored RNA Quant SARS-CoV-2 Control targets the SARS-CoV-2 viral nucleocapsid (N) region and, along with the companys new RNAse P construct, aligns with the CDC and WHO-recommended Diagnostic Panel (CDC-006-00019) to provide a safe, stable, and reliable way to test for the novel coronavirus.
  • Armored technology encapsulates the in vitro transcribed RNA in a protective protein coat to resist nuclease degradation, enabling its use as RNA extraction, process quality, and positive diagnostic reference controls.

Healthcare Communication Platform, Pulsara, Announces Release of FREE COVID-19 Management Package

Retrieved on: 
Sunday, March 15, 2020
Articles, Viruses, Health, Zoonoses, Coronaviridae, Health informatics, Animal virology, Coronavirus, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Telehealth, mHealth

BOZEMAN, Mont., March 15, 2020 /PRNewswire/ --Pulsara announced today that they have released a COVID-19 management package available to all EMS and healthcare organizations in the United States for free.

Key Points: 
  • BOZEMAN, Mont., March 15, 2020 /PRNewswire/ --Pulsara announced today that they have released a COVID-19 management package available to all EMS and healthcare organizations in the United States for free.
  • There are several ways clinicians can use the mHealth Pulsara communication platform to help their teams manage patients with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
  • During the pandemic, Pulsara for COVID-19 is free for teams using the platform for ANY combination of these goals.
  • Leverage video telemedicine and messaging for medical control scenarios, transporting only the patients who absolutely need to visit the hospital.

QIAGEN Gains BARDA Funding for Approval Process of QIAstat-Dx Test Kit for SARS-CoV-2 Coronavirus

Retrieved on: 
Friday, March 13, 2020
Infectious diseases, Pharmaceutical, Health, Clinical trials, Viruses, Nidovirales, Coronaviridae, Zoonoses, Animal virology, Coronavirus, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Barda, CoV, In Saudi Arabia

Accelerated development of the QIAstat-Dx test kit further expands QIAGENs global mobilization for the emergency, which already includes a dramatic increase in production of components for a full range of U.S. and international testing protocols.

Key Points: 
  • Accelerated development of the QIAstat-Dx test kit further expands QIAGENs global mobilization for the emergency, which already includes a dramatic increase in production of components for a full range of U.S. and international testing protocols.
  • QIAGENs QIAstat-Dx solution to help in the response to COVID-19 disease becomes the first syndromic testing product selected for development through ASPR's Biomedical Advanced Research and Development Authority (BARDA) streamlined selection process, known as an easy broad agency announcement (EZ-BAA).
  • BARDA will contribute $598,000 to accelerate QIAGEN's evaluation of the testing cartridge that detects the genetic material of SARS-CoV-2, the virus that causes COVID-19.
  • QIAGENs panel will include assays targeting two genes used to detect the pathogen behind the disease, Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2).

Enanta Pharmaceuticals Announces Efforts to Discover a Treatment for the Novel Coronavirus Disease COVID-19

Retrieved on: 
Friday, March 13, 2020
Health, FDA, Infectious diseases, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Viruses, Animal virology, Zoonoses, Coronavirus, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Antiviral drug, Coronaviridae, Bat SARS-like coronavirus WIV1, Coronavirus Disease, Enanta

Enanta is taking a two-pronged approach to its COVID-19 discovery efforts.

Key Points: 
  • Enanta is taking a two-pronged approach to its COVID-19 discovery efforts.
  • It is testing compounds from its antiviral compound library for potential activity against COVID-19.
  • It is also initiating a drug discovery program using its expertise in direct-acting antiviral mechanisms to discover new candidates to treat COVID-19.
  • Coronavirus disease (COVID-19) is an infectious disease caused by a new virus (SARS-CoV-2) that had not been previously identified in humans.

AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19

Retrieved on: 
Thursday, March 12, 2020
Medical specialties, Medicine, Branches of biology, Zoonoses, Immunology, Severe acute respiratory syndrome-related coronavirus, Antibody, Severe acute respiratory syndrome

From this effort, AbCellera has identified over 500 unique fully human antibody sequences, the largest panel of anti-SARS-CoV-2 antibodies ever reported.

Key Points: 
  • From this effort, AbCellera has identified over 500 unique fully human antibody sequences, the largest panel of anti-SARS-CoV-2 antibodies ever reported.
  • The next step is to screen these antibodies to find the ones most effective in neutralizing SARS-CoV-2.
  • "AbCellera's platform has delivered, with unprecedented speed, by far the world's largest panel of anti-SAR-CoV-2 antibodies," said Carl Hansen, Ph.D., CEO of AbCellera.
  • AbCellera was founded in 2012, and completed a Series A financing round in 2018, which was led by DCVC Bio.

Bio-Rad Announces that Through its Exact Diagnostics Product Line, the Company has Launched a SARS CoV-2 Standard for Coronavirus (COVID-19) Testing

Retrieved on: 
Thursday, March 12, 2020
Science, Biotechnology, Research, Pharmaceutical, Health, Hospitals, Genetics, Clinical trials, Viruses, Animal virology, Zoonoses, Coronavirus, Severe acute respiratory syndrome-related coronavirus, Molecular diagnostics, Severe acute respiratory syndrome, Assay, Betacoronavirus, Coronaviridae

Bio-Rad is providing the SARS CoV-2 Standard to help labs validate their COVID-19 assay results and accelerate access to testing.

Key Points: 
  • Bio-Rad is providing the SARS CoV-2 Standard to help labs validate their COVID-19 assay results and accelerate access to testing.
  • The SARS CoV-2 Standard contains synthetic COVID-19 RNA transcripts and human genomic DNA, allowing laboratories to test the entire process of a molecular assay including extraction, amplification, and detection of the virus.
  • The SARS CoV-2 Standard helps to validate COVID-19 tests, which enables more laboratories to meet the growing demand for identification of this coronavirus.
  • Bio-Rads Exact Diagnostics product line is a leader in developing and manufacturing a broad range of innovative molecular diagnostics products designed to meet the quality control needs of clinical labs and assay manufacturers.

Twist Bioscience Announces Availability of Synthetic SARS-CoV-2 RNA Controls

Retrieved on: 
Thursday, March 12, 2020
Health, Infectious diseases, Genetics, Research, Science, Pharmaceutical, Biotechnology, Viruses, Nidovirales, Coronaviridae, Animal virology, Zoonoses, Severe acute respiratory syndrome-related coronavirus, Coronavirus, RNA splicing, Molecular biology, Severe acute respiratory syndrome, RNA, Middle East respiratory syndrome-related coronavirus

Twist Bioscience Corporation (Nasdaq: TWST) today announced the availability of two synthetic SARS-CoV-2 RNA Controls.

Key Points: 
  • Twist Bioscience Corporation (Nasdaq: TWST) today announced the availability of two synthetic SARS-CoV-2 RNA Controls.
  • Twist is offering two fully-synthetic SARS-CoV-2 RNA controls, available for distinct reference sequences:
    The Twist synthetic controls are designed based on two specific SARS-CoV-2 variants, cover the full viral genome and are sequence-verified.
  • In addition, Twist is able to create synthetic RNA controls from other strains or sequences of the virus, and can provide these custom controls within two weeks.
  • For more information on the Twist Synthetic SARS-CoV-2 RNA controls, please visit: https://www.twistbioscience.com/coronavirus-research-tools .